Method of Participation
Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time. The online post-test and evaluation can be accessed at: https://tinyurl.com/PFF17Supp. Inquiries may be directed to Global Academy for Medical Education at [email protected] or (973) 290-8225 or Postgraduate Institute for Medicine at (720) 895-5357.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Designated for 1.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Statement of Needs
Idiopathic pulmonary fibrosis (IPF) is a fatal disease with no cure. The median life expectancy for patients diagnosed with IPF is about 3 to 5 years. Diagnosis can be determined by computed tomography in about half of the cases; the remainder require more invasive surgical biopsy. Two medications have been approved for pulmonary fibrosis, but these treatments only delay disease progression. Other options for patients include oxygen supplementation, pulmonary rehabilitation, and symptom management. Researchers are actively engaged in improving diagnostic tools to make them more sensitive and less invasive. Others are studying patients at risk for pulmonary fibrosis to develop methods for earlier diagnosis. Many other research programs are investigating the underlying causes and the pathophysiology of pulmonary fibrosis as a means of finding targets for future therapy. Clinicians treating patients with pulmonary fibrosis need a familiarity with research in progress so they will understand the role of new treatments as they are approved and so they can identify clinical trials that might help their patients.
This supplement features summaries of presentations from PFF Summit 2017, a conference sponsored by the Pulmonary Fibrosis Foundation that brought together leading researchers, clinicians, and patients for wideranging lectures and discussions of current and future treatment for pulmonary fibrosis.
At the conclusion of this program, participants should be better able to:
- Describe the role of personalized medicine in the treatment of pulmonary fibrosis
- Demonstrate an understanding of the impact of genetic mutations on the course of idiopathic pulmonary fibrosis (IPF) and the risk of IPF in first-degree relatives
- Describe recent advances in pulmonary fibrosis pathogenesis, including research in aging and senescence, oxidative stress, matrix stiffness, biomarkers, and the innate immune system
- Engage a multidisciplinary care team to treat patients with IPF, by referral or collaboration
- Appropriately manage common symptoms of patients with IPF
- Appropriately refer patients with IPF for nonpharmacologic therapy
- Identify patients with IPF and their relatives who should be considered for referral for genetic counseling
- Select patients with IPF for referral for treatment of gastroesophageal reflux and obstructive sleep apnea
- Evaluate clinical trial data supporting the efficacy and safety of pirfenidone and nintedanib
- Select pharmacologic therapy for patients with IPF
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Mary Armanios, MD, has nothing to disclose.
Timothy S. Blackwell, MD, has nothing to disclose. Gregory P. Cosgrove, MD, FCCP, Consultant: Boehringer Ingelheim, Genentech, Global Blood Therapeutics. Grant/Research Support: Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Global Blood Therapeutics. Kevin R. Flaherty, MD, MS, FCCP, Consultant: Boehringer Ingelheim, Celgene, Sanofi Genzyme/Veracyte. Grant/Research Support: Boehringer Ingelheim, Genentech, Hoffmann-La Roche. Naftali Kaminski, MD, Consultant: Biogen, Boehringer Ingelheim, NuMedii, Pliant, Samumed, Third Rock. Receipt of Intellectual Property Rights/Patent Holder: Aerosolized T3, Lifemax. Lisa H. Lancaster, MD, FCCP, Consultant: Boehringer Ingelheim, Genentech, Global Blood Therapeutics. Grant/Research Support: Celgene, Global Blood Therapeutics, Hoffmann-La Roche. Jeffrey M. Trent, PhD, has nothing to disclose. Paul Wolters, MD, Consultant: Genentech, Hoffmann-La Roche. Grant/Research Support: Genentech, MedImmune. Lisa Young, MD, Royalty and Consultant: Boehringer Ingelheim.
The planning staff and content managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Global Academy for Medical Education Staff:
Mike LoPresti; Shirley V. Jones, MBA; Margaret McLaughlin, PhD; and Faith Frankel hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Postgraduate Institute for Medicine has nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.